These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37984124)

  • 21. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.
    Deng H; Kan A; Lyu N; Mu L; Han Y; Liu L; Zhang Y; Duan Y; Liao S; Li S; Xie Q; Gao T; Li Y; Zhang Z; Zhao M
    Liver Cancer; 2020 Jun; 9(3):338-357. PubMed ID: 32647635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
    Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
    Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression.
    Liu H; Han J; Lv Y; Zhao Z; Zheng S; Sun Y; Sun T
    J Nanobiotechnology; 2023 Jul; 21(1):208. PubMed ID: 37408047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.
    Wang H; Gao C; Li X; Chen F; Li G
    Sci Rep; 2024 Mar; 14(1):7140. PubMed ID: 38532022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy.
    Peng Q; Li S; Shi X; Guo Y; Hao L; Zhang Z; Ji J; Zhao Y; Li C; Xue Y; Liu Y
    Phytother Res; 2023 May; 37(5):1740-1753. PubMed ID: 36576358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.
    Li X; Gao L; Wang B; Hu J; Yu Y; Gu B; Xiang L; Li X; Li H; Zhang T; Wang Y; Ma C; Dong J; Lu J; Lucas A; Chen H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrahepatic inflammatory IgA
    Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.
    Deng H; Kan A; Lyu N; He M; Huang X; Qiao S; Li S; Lu W; Xie Q; Chen H; Lai J; Chen Q; Jiang X; Liu S; Zhang Z; Zhao M
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.
    Zhang XS; Zhou HC; Wei P; Chen L; Ma WH; Ding L; Liang SC; Chen BD
    World J Gastrointest Oncol; 2023 Dec; 15(12):2138-2149. PubMed ID: 38173440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8
    Qian J; Chen T; Wu Q; Zhou L; Zhou W; Wu L; Wang S; Lu J; Wang W; Li D; Xie H; Su R; Guo D; Liu Z; He N; Yin S; Zheng S
    Cancer Lett; 2020 Dec; 495():1-11. PubMed ID: 32949680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy.
    Zhang Y; Akhil V; Seo HS; Park HR; Kim SH; You SH; Liu Z; Kim SY; Sultonova RD; Min JJ; Hong Y
    Theranostics; 2024; 14(3):1195-1211. PubMed ID: 38323311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IRGM is a novel regulator of PD-L1 via promoting S6K1-mediated phosphorylation of YBX1 in hepatocellular carcinoma.
    Ru J; Lu J; Ge J; Ding B; Su R; Jiang Y; Sun Y; Ma J; Li Y; Sun J; Xu G; Tong R; Zheng S; Yang B; Wu J
    Cancer Lett; 2024 Jan; 581():216495. PubMed ID: 37993085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8
    Li S; Li K; Wang K; Yu H; Wang X; Shi M; Liang Z; Yang Z; Hu Y; Li Y; Liu W; Li H; Cheng S; Ye L; Yang Y
    Nat Commun; 2023 Nov; 14(1):7709. PubMed ID: 38001101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.
    Tanaka T; Koga H; Suzuki H; Iwamoto H; Sakaue T; Masuda A; Nakamura T; Akiba J; Yano H; Torimura T; Kawaguchi T
    Hepatol Int; 2024 Jun; 18(3):984-997. PubMed ID: 37553470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
    Kim KJ; Lee HW; Seong J
    J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quercetin/Anti-PD-1 Antibody Combination Therapy Regulates the Gut Microbiota, Impacts Macrophage Immunity and Reshapes the Hepatocellular Carcinoma Tumor Microenvironment.
    Wu R; Xiong J; Zhou T; Zhang Z; Huang Z; Tian S; Wang Y
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):327. PubMed ID: 38179731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion.
    Chen Z; Yu M; Zhang B; Jin L; Yu Q; Liu S; Zhou B; Yan J; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Li H; Guo L
    Oncoimmunology; 2024; 13(1):2376264. PubMed ID: 38988824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.